ELDN

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for people requiring organ or cell-based transplants and for people with autoimmune and inflammatory diseases. The company's lead product candidate, tegoprubart, is a monoclonal antibody targeting CD40 Ligand, a key mediator of immune activation. Eledon is conducting clinical trials evaluating tegoprubart in kidney transplant recipients and in amyotrophic lateral sclerosis (ALS). The company's scientific approach aims to address the limitations of current immunosuppressive therapies by providing more selective immune modulation.